Skip to main content
. 2012 Nov;56(11):5511–5519. doi: 10.1128/AAC.00821-12

Table 3.

Main baseline characteristics and clinical outcomes of the 15 patients who developed virologic breakthrougha

Patient no. Age (yr) Gender HBeAg/anti-HBe HBV DNA at baseline (IU/ml) Liver cirrhosis ALT (IU/liter)
 Underlying malignancy HBV DNA at VB (IU/ml) Mutational pattern of genotypic resistance Duration of LAM (days) Time to VB after last chemotherapy (days) Rescue therapy Clinical course
Baseline Peak
1 57 M +/+ 6.81 × 105 Yes 22 48 Stomach cancer 2.60 × 106 M204I 513 113 LAM + ADV Improvement
2 43 M −/+ 1.39 × 102 No 72 924 NHL 1.64 × 104 L180M 312 32 Maintenance of LAM Death due to disease progression
3 68 M +/− 2.36 × 107 No 38 537 Colorectal cancer 5.61 × 106 L180M M204V 704 35 Switch to ETV Improvement
4 63 M +/− 3.44 × 104 No 45 162 Colorectal cancer 1.75 × 107 L180M M204V 536 222 Withdrawal of LAM Improvement
5 40 M −/+ 7.02 × 103 No 39 257 Leukemia 1.89 × 105 V173L M204I 502 343 Switch to ETV Improvement
6 60 M −/+ 1.55 × 107 No 28 92 NHL >1.1 × 108 M204I 288 182 LAM + ADV Death due to hepatic failure
7 52 F +/− >1.1 × 108 No 67 40 Stomach cancer 7.69 × 106 (i) L180M M204V (ii) L180M M204V S202G 435 258 (i) Switch to ETV, (ii) LAM + ADV Improvement
8 45 M −/+ 3.75 × 104 Yes 52 30 HCC 2.83 × 103 NIb 350 78 Maintenance of LAM Death due to disease progression
9 55 M +/− 1.09 × 108 No 29 38 NHL >1.1 × 108 NI 462 343 Maintenance of LAM Improvement
10 68 M −/+ 8.78 × 103 Yes 25 107 Stomach cancer 2.18 × 104 NI 12 21 Switch to ADV Improvement
11 66 F −/+ 2.10 × 10 No 7 26 Multiple myeloma 1.82 × 103 NI 301 7 Maintenance of LAM Improvement
12 64 M −/+ 1.20 × 106 Yes 26 17 Stomach cancer 8.90 × 103 NI 161 39 Maintenance of LAM Death due to disease progression
13 35 M +/− >1.1 × 108 No 54 179 NHL >1.1 × 108 NI 1,156 16 Maintenance of LAM Improvement
14 49 F +/− >1.1 × 108 No 12 17 NHL 7.12 × 106 NI 328 186 Withdrawal of LAM Improvement
15 27 F +/− >1.1 × 108 No 11 29 NHL 3.75 × 106 NI 75 27 Switch to ETV Improvement
a

F, female; M, male; ADV, adefovir; anti-HBe, hepatitis B e antibody; ETV, entecavir; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; LAM, lamivudine; NHL, non-Hodgkin's lymphoma; VB, virologic breakthrough.

b

NI, not identifiable. The sensitivity of the assay for HBV mutations was 357 IU/ml, and no mutation associated with drug resistance was found using DNA genotyping.